ASH – ½º¸¶Æ®Çコ ½ÉÆ÷Áö¾ö (¿Â,¿ÀÇÁ¶óÀÎ µ¿½Ã°³ÃÖ)_1ÀÏÂ÷ : 2024-02-17
±³À°ÀÏÀÚ : 2024-02-17
±³À°Àå¼Ò : ¼¿ï ´õÄÉÀÌÈ£ÅÚ °Å¹®°íȦ B
±³À°ÁÖÁ¦ : ASH – ½º¸¶Æ®Çコ ½ÉÆ÷Áö¾ö (¿Â,¿ÀÇÁ¶óÀÎ µ¿½Ã°³ÃÖ)_1ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ½º¸¶Æ®Çコ¿¬±¸È¸
´ã´çÀÚ : À̺¸¶ó
¿¬¶ôó : 02-2072-2043
À̸ÞÀÏ : ksmart.health@gmail.com
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 09:00~09:15 Exercise recommendation in HCM; Recent updates ÀÌÇöÁ¤(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 09:15~09:30 Utility of CMR in comparison to echo; Radiologist ÀÌÀ±¼º(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 09:30~09:45 Staging LV ejection fraction in HCM; Rationale and its clinical implication ÃÖÀ¯Á¤(°í·Á´ëÇб³±¸·Îº´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 09:45~10:00 Assessment of LV diastolic function in HCM; Conventional and novel echo markers ±èÇü°ü(¼¿ï´ëÇб³º´¿ø)
Åä·Ð 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 10:00~10:20 Discussion ( )
ÈÞ½Ä 02¿ù 17ÀÏ 10:20~10:35 Break ( )
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 10:35~10:50 Effects of Mavacamten for oHCM with vs without hypertension; insights from EXPLORER-HCM trial Andrew Wang(Duke University School of Medicine)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 10:50~11:05 Sex differences of Mavacamten treatment for HCM Andrew Wang(Duke University School of Medicine)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 11:05~11:20 Surgical septal myectomy in HCM: techniques, outcome and more ±è°æȯ(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 11:20~11:35 Anesthesiologist ÀüÀ±¼®(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 11:35~11:45 Hypertrophic Cardiomyopathy I ¹ÚÂù¼ø(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 11:45~11:55 Hypertrophic Cardiomyopathy II Á¶µ¿Çõ(°í·Á´ëÇб³¾È¾Ïº´¿ø)
Åä·Ð 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 11:55~12:25 Discussion ( )
½Ä»ç 02¿ù 17ÀÏ 12:25~13:15 Lunch ( )
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 13:15~13:30 EKG-based risk prediction, would it be valid in cardiomyopathies? ±ÇÁظí(¸ÞµðÄÿ¡À̾ÆÀÌ)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 13:30~13:50 AI-based risk prediction of cardiomyopathy using noninvasive imaging À±¿¬ÀÌ(ºÐ´ç¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 13:50~14:10 ICD prevention for cardiomyopathies, a word from the electrophysiologist ¹Ú½ÂÁ¤(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 14:10~14:25 Remote monitoring of cardiac implantable electronic device, implications for cardiomyopathy patients ÃÖÁ¾ÀÏ(°í·Á´ëÇб³¾È¾Ïº´¿ø)
Åä·Ð 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 14:25~14:45 Discussion ( )
ÈÞ½Ä 02¿ù 17ÀÏ 14:45~15:00 Break ( )
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 15:00~15:15 Learnings from the amyloidosis database in Korea ±è´Ù·¡(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 15:15~15:30 Amyloidopathies in neurologic disease ½ÅÁ¦¿µ(ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 15:30~15:45 Radioisotope imaging in cardiac amyloidosis ÆØÁøö(¼¿ï´ëÇб³º´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 15:45~16:00 Gathering the evidence for evaluation of cardiac amyloidosis À̽ÂÇ¥(¼¿ï´ëÇб³º´¿ø)
Åä·Ð 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 16:00~16:20 Discussion ( )
ÈÞ½Ä 02¿ù 17ÀÏ 16:20~16:30 Break ( )
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 16:30~16:50 Diverse manifestations of cardiac amyloidosis - how not to miss Pablo Garcia-Pavia(Hospital Universitario Puerta de Hierro Majadahonda)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 16:50~17:05 Heart transplantation in cardiac amyloidosis, why it ¿ÀÀç¿ø(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 17:05~17:25 Development of novel therapeutics for cardiac amyloidosis Pablo Garcia-Pavia(Hospital Universitario Puerta de Hierro Majadahonda)
±³À°½Ã°£ 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 17:25~17:35 Cardiac Amyloidosis ÃÖÈ«¹Ì(ºÐ´ç¼¿ï´ëÇб³º´¿ø)
Åä·Ð 02¿ù 17ÀÏ °Å¹®°íȦ B, ¿Â¶óÀÎ 17:35~17:55 Discussion ( )